Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Sinovac Biotech Ltd (SVA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/08/2025: SVA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit 0% | Avg. Invested days 0 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/08/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 642.44M USD | Price to earnings Ratio 6.66 | 1Y Target Price 3.52 |
Price to earnings Ratio 6.66 | 1Y Target Price 3.52 | ||
Volume (30-day avg) - | Beta 0.06 | 52 Weeks Range 6.47 - 6.47 | Updated Date 04/11/2025 |
52 Weeks Range 6.47 - 6.47 | Updated Date 04/11/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.97 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 21.61% | Operating Margin (TTM) 42.26% |
Management Effectiveness
Return on Assets (TTM) 11.46% | Return on Equity (TTM) 25.16% |
Valuation
Trailing PE 6.66 | Forward PE - | Enterprise Value 297087285 | Price to Sales(TTM) 1.83 |
Enterprise Value 297087285 | Price to Sales(TTM) 1.83 | ||
Enterprise Value to Revenue 0.03 | Enterprise Value to EBITDA 0.04 | Shares Outstanding 99294704 | Shares Floating 59508332 |
Shares Outstanding 99294704 | Shares Floating 59508332 | ||
Percent Insiders 51.42 | Percent Institutions 32.02 |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Sinovac Biotech Ltd
Company Overview
History and Background
Sinovac Biotech Ltd. was founded in 2001. It is a biopharmaceutical company focused on the research, development, manufacturing, and commercialization of vaccines for human diseases. A significant milestone was the development and approval of CoronaVac, its COVID-19 vaccine.
Core Business Areas
- Vaccine Development and Manufacturing: Sinovac's core business is developing and manufacturing vaccines for various diseases, including COVID-19, influenza, hepatitis, and others.
- Research and Development: The company invests heavily in R&D to discover and develop new vaccines and improve existing ones.
- Commercialization: Sinovac commercializes its vaccines through partnerships with distributors and direct sales in some markets.
Leadership and Structure
Details about Sinovac's leadership team and organizational structure are not readily available in public sources that can be verified; the information can change frequently. A review of Sinovac's investor relations website, if available, would be advisable.
Top Products and Market Share
Key Offerings
- CoronaVac (COVID-19 Vaccine): An inactivated COVID-19 vaccine. Market share information varies by region, but it has been a significant player in several countries, particularly in Asia and South America. Competitors include Pfizer/BioNTech, Moderna, AstraZeneca, and Johnson & Johnson.
- Healive (Hepatitis A Vaccine): A vaccine for Hepatitis A. Specific market share data is not easily accessible, but it competes with other Hepatitis A vaccines from companies like Merck.
- Anflu (Influenza Vaccine): An influenza vaccine. Market share data varies seasonally and by region. Competitors include Seqirus, Sanofi, and GSK.
Market Dynamics
Industry Overview
The vaccine industry is characterized by high barriers to entry, stringent regulatory requirements, and significant R&D investments. Demand for vaccines is driven by public health concerns, government immunization programs, and emerging infectious diseases.
Positioning
Sinovac is positioned as a key player in the vaccine market, particularly in emerging markets. Its competitive advantage lies in its established manufacturing capabilities and its focus on developing vaccines for diseases prevalent in these regions.
Total Addressable Market (TAM)
The global vaccine market is estimated to be hundreds of billions of dollars, with the global vaccines market projected to reach $95.5 billion by 2028. Sinovac is positioned to address a portion of this TAM, particularly in regions where its vaccines are approved and distributed.
Upturn SWOT Analysis
Strengths
- Established manufacturing capabilities
- Strong presence in emerging markets
- Experience in developing and commercializing vaccines
- Proven ability to rapidly develop vaccines during pandemics (CoronaVac)
Weaknesses
- Limited presence in developed markets
- Potential reliance on a few key products
- Geopolitical risks associated with being a Chinese company
Opportunities
- Expanding into new geographic markets
- Developing new vaccines for emerging infectious diseases
- Partnering with international organizations and governments
- Expanding research into mRNA vaccine technology
Threats
- Intense competition from established vaccine manufacturers
- Stringent regulatory requirements
- Potential for product liability claims
- Fluctuations in government funding for vaccination programs
- Intellectual property risks
Competitors and Market Share
Key Competitors
- PFE
- MRNA
- AZN
- JNJ
Competitive Landscape
Sinovac faces intense competition from established players with greater resources and broader market access. However, Sinovac's strengths in emerging markets and its ability to rapidly develop vaccines provide a competitive edge in certain regions.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth trends are unavailable without access to financial data when the company was publicly listed. It is now a private company.
Future Projections: Future projections are not available without access to financial data and analyst reports since the company is no longer publicly traded on a US exchange.
Recent Initiatives: Information on recent strategic initiatives would require access to private company communications or news releases, which are not generally available.
Summary
Sinovac Biotech possesses significant manufacturing and R&D experience, particularly in emerging markets, but faces challenges from competitors. The company has proven its ability to create vaccines rapidly. While it is now a private company which lacks transparency on market position, its success with CoronaVac positions it competitively. However, its limited presence in developed markets and geopolitical risks could limit growth.
Similar Companies
AZN
AstraZeneca PLC ADR
AZN
AstraZeneca PLC ADR
JNJ
Johnson & Johnson
JNJ
Johnson & Johnson
MRNA
Moderna Inc
MRNA
Moderna Inc
PFE
Pfizer Inc
PFE
Pfizer Inc
Sources and Disclaimers
Data Sources:
- Publicly available information.
- Financial news sources.
- Company press releases (when available).
- Third party market research reports
Disclaimers:
The information provided is based on available data and is subject to change. Market share estimates are approximate. The analysis is for informational purposes only and should not be considered investment advice. As the company is now private, data is more challenging to collect and analyze.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Sinovac Biotech Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2003-11-03 | Chairman, CEO, Pres, MD, GM & Sec. Dr. Weidong Yin | ||
Sector Healthcare | Industry Biotechnology | Full time employees 1959 | Website http://www.sinovacbio.com |
Full time employees 1959 | Website http://www.sinovacbio.com | ||
Sinovac Biotech Ltd., a biopharmaceutical company, focuses in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B; hand, foot, and mouth diseases caused by enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza; coronavirus; varicella; and mumps. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine to treat viral disease in human species; split viron pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company also offers varicella, a vaccine to treat contagious infectious disease; pneumococcal polysaccharide vaccine, a vaccine to prevent streptococcus pneumoniae infections, such as pneumonia and septicemia; quadrivalent influenza vaccine, a vaccine to protect against two influenza A viruses and two influenza B viruses; and CoronaVac, a vaccine against COVID-19. In addition, its pipeline products include sabin inactivated polio vaccine, a vaccine to treat Poliomyelitis that has completed phase III clinical trial; and rubella vaccine. The company has collaboration agreements with GlaxoSmithKline Biologicals SA to develop combination vaccines containing measles for the China market; Tianjin CanSino Biotechnology Inc. to develop a pneumococcal vaccine; and Instituto Butantan to advance the clinical trials of CoronaVac, an inactivated vaccine candidate against COVID-19 to Phase III. Sinovac Biotech Ltd. was founded in 1993 and is headquartered in Beijing, the People's Republic of China.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.